MRUS icon

Merus
MRUS

Overview Fund Trends Analyst Outlook Journalist POV
94.60 USD
--0.28
0.3%
At close Updated Oct 27, 4:00 PM EDT
Pre-market
After hours
94.51
--0.09
0.1%
1 day
-0.3%
5 days
0.1%
1 month
0.99%
3 months
44.23%
6 months
108.92%
Year to date
123.64%
1 year
79.1%
5 years
613.42%
10 years
842.23%
 

About: Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Employees: 260

Healthcare Biotechnology
0
Funds holding %
of 7,500 funds
Explore Fund Trends
0
Analysts bullish %
of 12 analysts
See Analyst Outlook
0
Positive news %
of 17 articles
Check Journalist POV
Price charts implemented using Lightweight Charts™